Sponsor

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Germany Ismaninger Strasse 22, Au-Haidhausen, 81675 Munich, Germany

About the sponsor

Clinical research at Klinikum rechts der Isar der TU Muenchen AöR includes idiopathic Parkinson's disease and corticobasal syndrome, with interest in symptomatic treatment, neurodegeneration, and biomarkers linked to disease progression.

Parkinson's disease
Corticobasal syndrome
Neurofilament light chain
ROCK inhibition

The neurological portfolio also reflects work on therapies aimed at motor and non-motor symptom control, alongside molecular measures relevant to neurodegenerative disease.

About Specializations

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) runs clinical trials in conditions such as Obesity, Seasonal allergy, Prostate cancer, Non-Hodgkin's lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

7 clinical trials

Obesity

Recruiting

Resistance Training to Preserve Thigh Muscle Volume in Adults with Obesity Treated with Tirzepatide (Phase IV Randomized Trial)

Registered drugNo placebo

Resistance Training to Preserve Thigh Muscle Volume in Adults with Obesity Treated with Tirzepatide (Phase IV Randomized Trial)

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Tirzepatide
Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Contact Research Centre

Seasonal allergy

Recruiting

Short‑course sublingual ITULAZAX birch pollen extract with Lactobacillus rhamnosus GG for patients with pollen‑associated food allergy

Registered drug

Short‑course sublingual ITULAZAX birch pollen extract with Lactobacillus rhamnosus GG for patients with pollen‑associated food allergy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Lactobacillus rhamnosus GG
Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Contact Research Centre

Prostate cancer

Not yet recruiting

Study of GOZETOTIDE PET/CT added to mpMRI for detecting clinically significant prostate cancer in men undergoing primary diagnosis

Registered drugNo placebo

Study of GOZETOTIDE PET/CT added to mpMRI for detecting clinically significant prostate cancer in men undergoing primary diagnosis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Contact Research Centre

Non-Hodgkin's lymphoma

Not yet recruiting

Study of [90Y]Y-PentixaTher and [68Ga]Ga-PentixaFor in patients with advanced Non-Hodgkin lymphomas: Evaluating radiopeptide-based imaging and therapy

InvestigationalNo placebo